Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • Design Duo 80 VF Business
  • Eventz Factory’s Bold & Beautiful & Super Mom, Super Woman Awards dot Mother’s Day Celebrations Business
  • Elevate Your Family Get-Together with These Gifts Business
  • Emerald Finance and Baya PTE Partner to Boost Bill Discounting for SME Suppliers to Large Firms Business
  • A New Health & Wellness Brand Is Making Some Noise in the Indian Market Business
  • Network Express Hosts Inspiring ‘Direct Selling Success Summit & Awards 2025’ in Mumbai Business
  • P & G Global Production introduces Mr Miss & Mrs Delhi Global Pageant Lifestyle
  • Common University Entrance Test (CUET), How Bestseller Books Revolutionize CUET Exam Preparation, Now prepare Smarter with eVidya CUET Exam Bestsellers Books Education

ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs

Posted on April 29, 2021 By

ISSAR Pharma, the only company in India which focuses on the research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, opening opportunities for fruitful partnerships.

Hyderabad (Telangana) [India], April 29: ISSAR Pharmaceuticals, the Pioneer in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent. The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population and making them affordable and accessible for better health outcomes.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses Solid-phase peptide synthesis as the technology of choice and has the capability to synthesize custom peptides, API peptides, and cosmetic peptides at all scales within a short duration. With an emphasis on quality, safety, and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life-changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology, and diseases of bones and joints.

“We take pride in being India’s first-ever company to conduct phase-1 clinical trials and launch the first-ever indigenous peptide drug, Melgain in the market for the treatment of Vitiligo in 2004”, informs Mr. Ramakrishna Reddy Isanaka, the founder of ISSAR. ISSAR’s

FDA- compliant state-of-the-art manufacturing facility of 62000 sq. ft., is purely into peptide manufacturing technology, located in Genome Valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing the highest standards of purity of up to 99.5% by continued process optimization.

With over 25 years of experience and a prime focus in Research and Development, ISSAR’s dedicated team of experts is proud to have developed India’s first-ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’s commitment has also led to the development of their second New Chemical Entity called Xylentra, which is the first-ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis, and Sepsis. Recently, an NCE for the treatment of burn wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, the USA in 2020.

ISSAR Pharmaceuticals was founded by Mr. Ramakrishna Reddy Isanaka in 1995 with a vision to be a global leader in peptide drug discovery for improving patients’ quality of life. Before starting ISSAR Pharmaceutical, Mr.Isanaka was the promoter and director of Shantha Biotechnics in the 1980s, at a time when Biotechnology was new to India.

His efforts in research and development led to the advancement of ISSAR Pharma as the first-ever company in India to conduct Phase-I Clinical Trials in the year 1995. Today, he has over 25 years of experience in the development of NCEs with 2 successfully commercialized products, 7 plus patents to his credit, and over 6 commercially viable products under development.

https://issar.co.in/

English, Health, Press Release Tags:ISSARPharma, PeptidebasedNCEs, PNN

Post navigation

Previous Post: Glimpse up the world @worldwithmaria
Next Post: Indian Furniture Rental Industry – Market Size, Growth & Scope

Related Posts

  • National and international scientists disseminate research findings and discuss policy implications Press Release
  • UK University Fair 2022 at Shangri-La Eros, New Delhi Press Release
  • Toyam Sports Limited Returns for World Tennis League Season 3 As The Owners of Team Hawks Press Release
  • DPS Bhagalpur and DPS Greater Ranchi’s celebration of Azadi Ka Amrit Mahotsav with the 75-meter-long national flag march got included in the World Book of Records Press Release
  • Fateh TV enters its 8th-year journey of broadcasting 24×7 Gurbani around the globe English
  • Adell Kimbrough: The top entrepreneur transforming several lives towards a glorious future Press Release

Recent Posts

  • Aayush Wellness Launches Brain Fuel Capsules
  • India’s AI Future Begins Here: Scaler School of Technology’s New-Age Engineering Blueprint
  • Protyze Launches HYDRA-X: India’s An Advanced Clear Protein with Electrolytes, Creatine & Glutamine.
  • IMS Ghaziabad (University Courses Campus) and Dainik Jagran Honor Academic Excellence at the ‘Pratibha Samman’ Ceremony
  • Vedic Meet – India’s Leading Problem-Solving App for Online Astrology

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Gujarat Tourism Takes Center Stage at the Iconic Gold Awards 2025 Lifestyle
  • Hello Entrepreneurs’ columnist and well-known environmentalist Viral Desai felicitated with the National Energy Conservation award by the President of India Business
  • Dr. Ravul Jindal: A Global Leader Bridging Healthcare and Humanity Health
  • Insta Food CEO Piyush Sheta Envisions Growth and Innovation in Ready-to-Cook Sector with 2025 Union Budget Business
  • Balusingh Rajpurohit along with Junjaram Thory started a fact-checking campaign for a fair understanding of Covid-19 A
  • Six Dreams Unveils Engaging Esports Fantasy Application Experience for Cricket and Esports Fans Press Release
  • Cappella Educore expands student housing footprint with new acquisition in Bengaluru Press Release
  • Migrate World presents Global Webinar Series: USA & Canada Residency by Investment Business

Copyright © 2025 Daily News India.

Powered by PressBook News WordPress theme